{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:16:58Z","timestamp":1791433018165,"version":"4.3.3"},"reference-count":43,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100013058","name":"Jiangsu Provincial Key Research and Development Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","celltherapyjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jcyt.2024.03.481","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T16:45:15Z","timestamp":1711730715000},"page":"832-841","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Complex association of body mass index and outcomes in patients with relapsed and refractory multiple myeloma treated with CAR-T cell immunotherapy"],"prefix":"10.1016","volume":"26","author":[{"given":"Hai","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yegan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunming","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlin","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junnian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3767-9283","authenticated-orcid":false,"given":"Jiang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2024.03.481_bib0001","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/bjh.14470","article-title":"Recent advances in T-cell immunotherapy for haematological malignancies","volume":"176","author":"Rouce","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0002","doi-asserted-by":"crossref","first-page":"e120505","DOI":"10.1172\/jci.insight.120505","article-title":"Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma","volume":"3","author":"Garfall","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0003","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0004","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0005","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0006","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1038\/s41375-019-0516-7","article-title":"Humanized CD19-specific chimeric antigen-receptor T-cells in 2 adults with newly diagnosed B-cell acute lymphoblastic leukemia","volume":"33","author":"Cao","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0007","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0008","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0009","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0010","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0011","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0012","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature21363","article-title":"Inflammation, metaflammation and immunometabolic disorders","volume":"542","author":"Hotamisligil","year":"2017","journal-title":"Nature"},{"issue":"Suppl 3","key":"10.1016\/j.jcyt.2024.03.481_bib0013","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/dom.12154","article-title":"The immune cells in adipose tissue","volume":"15","author":"Ferrante","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0014","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/cncr.34529","article-title":"Body mass index during maintenance therapy and relapse risk in children with acute lymphoblastic leukemia: a Children's Oncology Group report","volume":"129","author":"Wadhwa","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0015","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood-2014-08-595389","article-title":"Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia","volume":"124","author":"Orgel","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0016","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1182\/bloodadvances.2020004018","article-title":"Caloric and nutrient restriction to augment chemotherapy efficacy for acute lymphoblastic leukemia: the IDEAL trial","volume":"5","author":"Orgel","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0017","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/bmt.2014.71","article-title":"The skinny on obesity and plasma cell myeloma: a review of the literature","volume":"49","author":"Carson","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0018","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1470-2045(18)30078-0","article-title":"Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis","volume":"19","author":"McQuade","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0019","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.3390\/cancers12051230","article-title":"The effects of obesity on anti-cancer immunity and cancer immunotherapy","volume":"12","author":"Woodall","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0020","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/ajcn\/nqaa258","article-title":"Adiposity and mortality in Korean adults: a population-based prospective cohort study","volume":"113","author":"Oh","year":"2021","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0021","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0022","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/ajh.25108","article-title":"Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"93","author":"Cao","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0023","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0024","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0025","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1200\/JCO.2011.39.2100","article-title":"Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma","volume":"30","author":"Carson","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0026","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ctrv.2008.07.005","article-title":"Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA)","volume":"35","author":"Hunter","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0027","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1200\/JCO.1988.6.8.1321","article-title":"Doxorubicin clearance in the obese","volume":"6","author":"Rodvold","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0028","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.bbmt.2010.04.009","article-title":"Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) in adults","volume":"16","author":"Navarro","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0029","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.bbmt.2005.12.033","article-title":"Effect of body mass index on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation","volume":"12","author":"Navarro","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0030","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1182\/bloodadvances.2019000923","article-title":"Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield","volume":"4","author":"Farhadfar","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0031","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.bbmt.2013.07.018","article-title":"Sex and body mass index but not CXCL12 801 G\/A polymorphism determine the efficacy of hematopoietic cell mobilization: a study in healthy volunteer donors","volume":"19","author":"Lenk","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0032","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.transci.2017.05.021","article-title":"Factors affecting hematopoietic stem cell mobilization and apheresis in allogeneic donors: the role of iron status","volume":"56","author":"\u00d6zkurt","year":"2017","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0033","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.3390\/jcm11144169","article-title":"Correlation of body mass index and proinflammatory cytokine levels with hematopoietic stem cell mobilization","volume":"11","author":"Wang","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0034","article-title":"Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0035","article-title":"Prolonged hematological toxicity in patients receiving BCMA\/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0036","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41568-021-00363-z","article-title":"Interleukins in cancer: from biology to therapy","volume":"21","author":"Briukhovetska","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0037","doi-asserted-by":"crossref","first-page":"eaba1624","DOI":"10.1126\/science.aba1624","article-title":"Synthetic cytokine circuits that drive T cells into immune-excluded tumors","volume":"378","author":"Allen","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0038","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1158\/2643-3230.BCD-21-0181","article-title":"Blockade or deletion of IFN\u03b3 reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies","volume":"3","author":"Bailey","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0039","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41586-022-04585-5","article-title":"CAR T cell killing requires the IFN\u03b3R pathway in solid but not liquid tumours","volume":"604","author":"Larson","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0040","doi-asserted-by":"crossref","first-page":"eabd4344","DOI":"10.1126\/sciimmunol.abd4344","article-title":"A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity","volume":"6","author":"Boulch","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0041","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s43018-023-00570-7","article-title":"Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-\u03b3 is a major determinant of CD4(+) CAR T-cell antitumor activity","volume":"4","author":"Boulch","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0042","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1158\/0008-5472.CAN-03-1753","article-title":"Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity","volume":"64","author":"Curnis","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2024.03.481_bib0043","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.cmet.2018.05.012","article-title":"Alteration of tumor metabolism by CD4+ T cells leads to TNF-\u03b1-dependent intensification of oxidative stress and tumor cell death","volume":"28","author":"Habtetsion","year":"2018","journal-title":"Cell Metab"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924005723?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924005723?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T18:57:47Z","timestamp":1721674667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324924005723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1465324924005723"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.03.481","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complex association of body mass index and outcomes in patients with relapsed and refractory multiple myeloma treated with CAR-T cell immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.03.481","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}